Lucanthone

DB04967InvestigationalSmall molecule

One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation...

Mechanism: Recent data suggests that lucanthone inhibits post-radiation DNA repair in tumor cells. The ability of lucanthone to inhibit AP endonuclease and topoisomerase II probably account for the specific DNA repair inhibition in irradiated cells.
Curator reviewed
Primary indication: Intended for use as a radiation sensitizer in the treatment of brain cancer.Curator reviewed
Formula / weight: C₂₀H₂₄N₂OS · 340.482 g/mol (avg)

Resolves to

Compound

UNIIFC6D57000MCAS479-50-5ChEMBLCHEMBL279014ChEBI51052PubChem10180KEGGC11715

Clinical / RWD

PharmGKBPA164748783

Structure

InChIKeyFBQPGGIHOFZRGH-UHFFFAOYSA-NSMILESCCN(CC)CCNC1=C2C(=O)C3=CC=CC=C3SC2=C(C)C=C1

Targets

P11388TOP2AP27695APEX1P11387TOP1Q02880TOP2B

What you can answer from here — as of September 13, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lucanthone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account